Date: Friday, September 13, 2019
Time: Registration and Breakfast at 6:00 AM | Educational Activity from 6:15 AM - 7:45 AM
Location: Hilton Americas-Houston | Grand Ballroom, Level 4, A/B/D/E
CAR T cells have emerged as a highly effective therapy in patients with hematologic malignancies. However, multiple CAR T technologies are under investigation, all with varied doses, lymphodepleting chemotherapy, disease subtypes under exploration, and adverse event profiles. This symposium will be presented by 3 world-renowned experts actively treating patients with these agents and provide expert guidance to evaluate clinical data of CAR T therapy and plan strategies to appropriately integrate these approaches into practice now and as they become available.
This activity is intended for community and academic medical oncologists, hematologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with lymphoma and myeloma and who attend the SOHO Annual Meeting.
After completing this activity, the participant should be better able to:
- Understand the mechanism of action of CAR T-cell-based therapy and the rationale for their investigation and use in patients with lymphoma and multiple myeloma (MM)
- Evaluate clinical data of current and emerging CAR T-cell therapies for patients with lymphoma
- Assess clinical trial results from CAR T cells being investigated in patients with MM
- Anticipate adverse events that may occur with CAR T-cell therapy, and develop strategies to mitigate these AEs
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Bio Ascend, LLC. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
6:00 AM Registration and Breakfast
6:15 AM Welcome, Introductions, and Presession Survey
6:20 AM CAR T-Cell Overview: MOA and Rationale for Use
6:30 AM CAR T-Cell Therapy for Lymphoma: Current and Emerging Options
6:50 AM CAR T-Cell Therapy for Multiple Myeloma: The Future of Myeloma Care?
7:10 AM Ongoing Efforts to Improve the Safety of CAR T cell therapy: Cytokine Release Syndrome and Neurotoxicity
7:25 AM Lymphoma and Myeloma Tumor Board: Identifying Patients Appropriate for CAR T-cell Therapy
7:35 AM Audience Q&A
7:40 AM Recap of Key Points and Post-Session Survey
7:45 AM Adjourn
Julie M. Vose, MD, MBA - Chair
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology Department of Internal Medicine
University of Nebraska Medical Center
Bianca Santomasso, MD, PhD
Neuro-oncologist & Neurologist
Memorial Sloan Kettering Cancer Center
New York, New York
Disclosure of Commercial Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Space is limited and preregistration is recommended to reserve your seat. If your plans change and you are no longer able to attend, please cancel your registration to allow others to register. There is no fee to register for this activity.
American With Disabilities Act (ADA)
In compliance with the Americans with Disabilities Act, the Postgraduate Institute for Medicine does not discriminate on the basis of disability. The Postgraduate Institute for Medicine and Bio Ascend shall provide reasonable accommodations, including auxiliary aids and services, to ensure equal access to its activities and services. If you would like an auxiliary aid or service, please call 888-476-9129 or email email@example.com by 9/6/2019 with your request.
This activity is jointly provided by Postgraduate Institute for Medicine and Bio Ascend, LLC.
This activity is supported by independent educational grants from Celgene Corporation and Gilead Sciences, Inc.
Not an official event of the SOHO 2019 Annual Meeting. Not sponsored or endorsed by the Society of Hematologic Oncology.
Select the Continue button below to register.